Disease relevance of Deglutition Disorders

• More recently, it was shown that this original DFN-1 family represented a new type of recessive neurodegenerative syndrome characterized by postlingual progressive sensorineural deafness as the first presenting symptom in early childhood, followed by progressive dystonia, spasticity, dysphagia, mental deterioration, paranoia and cortical blindness [1].
• EGD was most commonly performed to evaluate dyspepsia and/or abdominal pain (23.7%), dysphagia (20%), symptoms of gastroesophageal reflux without dysphagia (17%), and suspected upper GI bleeding (16.3%) [2].
• At 6 months, omeprazole produced a significantly (P < 0.01) higher rate of esophagitis healing, dysphagia relief, and fewer dilatations compared with H2RA [3].
• Biotin-responsive basal ganglia disease (BBGD) is a recessive disorder with childhood onset that presents as a subacute encephalopathy, with confusion, dysarthria, and dysphagia, and that progresses to severe cogwheel rigidity, dystonia, quadriparesis, and eventual death, if left untreated [4].
• Rapid-onset dystonia-parkinsonism (RDP) is characterized by sudden onset over hours to days of dystonia, dysphagia, dysarthria, and parkinsonism [5].

Psychiatry related information on Deglutition Disorders

• The dysphagia of ALS is characterized by an impaired oral stage of swallowing, which has a direct impact on the seemingly more robust pharyngeal stage [6].
• Dementia, dysphagia, dystonia and seizures, in that sequence, followed within a couple of years [7].

High impact information on Deglutition Disorders

• All 13 patients had pressurelike pain, ten had dysphagia, and six had symptoms of gastroesophageal reflux [8].
• A woman had cervical C-1 to C-2 subluxation with dysphagia [9].
• AGA technical review on management of oropharyngeal dysphagia [10].
• On completion, symptom relief favored omeprazole: 76% of patients in the omeprazole group were free of dysphagia (compared with 64% in the ranitidine group; P < 0.05); 83% were able to accept a normal diet (69%; P < 0.01); and 65% were completely asymptomatic (43%; P < 0.001) [11].
• The manometric findings of deglutitive pharyngoesophageal function in a patient with the Kearns-Sayre syndrome and cervical dysphagia are described [12].

Chemical compound and disease context of Deglutition Disorders

• Ethanol-induced tumour necrosis for palliation of malignant dysphagia [13].
• Subjectively, 13 patients had their dysphagia relieved by isosorbide dinitrate and 8 by nifedipine [14].
• In addition, bethanechol significantly increased abnormal motility and increased dysphagia during food ingestion in the patients, but was without significant effect in controls [15].
• Dilatation of the strictures followed by treatment with histamine H2-antagonists produced almost complete resolution of dysphagia in both patients [16].
• Chronic dysphagia and trigeminal anesthesia after trichloroethylene exposure [17].

Biological context of Deglutition Disorders

• Involvement of the dorsal motor nucleus of the vagus might produce dysfunction of muscles controlling deglutition and esophageal motility, thereby leading to drooling, dysphagia, and gastroesophageal reflux [18].
• When clinical, radiological and manometric data in the seven patients developing peristalsis were compared with findings in the other 20, there were no differences in symptoms, lower oesophageal sphincter pressures and lengths, relief of dysphagia or oesophageal calibre reduction [19].
• Patients with fluconazole resistance had lower CD4+ cell counts at baseline; more symptoms (P = .0006); a higher frequency of dysgeusia (P = .004), dysphagia (P = .006), and throat pain (P = .0034); and greater oral coverage by plaques of Candida [20].
• The beneficial effects are described of surgery in relieving severe dysphagia and stridor, and of prednisone in softening and shrinking the hard neck mass [21].
• BACKGROUND: Congenital cricopharyngeal achalasia is a rare condition in which a newborn presents with dysphagia, choking, nasal reflux, and salivation [22].

Anatomical context of Deglutition Disorders

• AGA technical review on treatment of patients with dysphagia caused by benign disorders of the distal esophagus [23].
• September 1999: 24 year old female with progressive lower extremity dystonia, dysarthia, dysphagia and mental impairment [24].
• At onset, it appears as a subacute encephalopathy, with confusion, dysarthria and dysphagia with occasional supranuclear facial nerve palsy or external ophthalmoplegia, and progresses to severe cogwheel rigidity, dystonia and quadriparesis [25].
• Pyramidal tract signs, pale discs and dysphagia were more frequent in SCA1 compared SCA2 and SCA3 patients [26].
• Affected members presented with the classical features of OPMD, namely ptosis, dysphagia and cytoplasmic inclusions on muscle biopsy, although with some atypical features, such as early age of onset, high serum levels of creatine kinase and a profound ophthalmoplegia [27].

Gene context of Deglutition Disorders

• Pank2 mice are 20% decreased in weight when compared with their wild-type littermates; however, dysphagia was not apparent [28].
• Haploinsufficiency of the PAX9 gene might be expected to cause some of the developmental defects and the dysphagia [29].
• Patients with dysphagia and coexisting myelopathy benefit from simultaneous surgery for resection of OALL and OPLL masses [30].
• Percutaneous endoscopic gastrostomy (PEG) provides a reliable route for nutrition and hydration in ALS patients with dysphagia [31].
• CD4 lymphocyte count and CD4/CD8 ratio in elderly long-term care patients with oropharyngeal dysphagia: comparison between oral and tube enteral feeding [32].

Analytical, diagnostic and therapeutic context of Deglutition Disorders

• Although the major goals of anti-reflux procedure are clearly achieved in many severely impaired children with gastroesophageal reflux, the use of Nissen fundoplication to resolve the complications of swallowing disorders and improve outcome with an acceptably low risk in this complex set of patients does not appear to be established [33].
• A randomised prospective comparison of the Flamingo Wallstent and Ultraflex stent for palliation of dysphagia associated with lower third oesophageal carcinoma [34].
• A significantly lower incidence of reoperation for failure (1.6% versus 9.6%, OR 0.21, RD -7%, NNT 14) was found after partial fundoplication, with no significant differences regarding the incidence of recurrence and/or dysphagia [35].
• METHODS AND MATERIALS: A total of 26 patients receiving RT concurrent with gemcitabine, a regimen associated with a high rate of late dysphagia and aspiration, underwent prospective evaluation of swallowing with videofluoroscopy (VF), direct endoscopy, and CT [36].
• Prednisone was continued with a slow taper, and after 1 month ber dysphagia had resolved and her esophageal manometry was normal [37].

References